502 149

Full metadata record

DC FieldValueLanguage
dc.contributor.author황승용-
dc.date.accessioned2017-11-06T04:27:40Z-
dc.date.available2017-11-06T04:27:40Z-
dc.date.issued2016-01-
dc.identifier.citationBMC CANCER, v. 16, Article number 27, Page. 1-9en_US
dc.identifier.issn1471-2407-
dc.identifier.urihttps://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2049-z-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/30478-
dc.description.abstractBackground: Biopsy for lung cancer diagnosis is usually done at a single site. But it is unclear that genetic information at one biopsy site represents that of other lesions and is sufficient for therapeutic decision making. Methods: Non-synonymous mutations and insertions/deletions of 16 genes containing actionable mutations, and intron 2 deletion polymorphism of Bcl2-like11 were analyzed in 41 primary tumor and metastatic lymph node (L/N) matched, pStage IIA similar to IIIA non-small cell lung cancer (NSCLC) samples using a next generation sequencing based technique. Results: A total of 249 mutations, including 213 non-synonymous mutations, 32 deletions, and four insertions were discovered. There was a higher chance of discovering non-synonymous mutations in the primary tumors than in the metastatic L/N (138 (64.8%) vs. 75 (35.2%)). In the primary tumors, 106 G ˃ A:C ˃ T transitions (76.8%) of 138 non-synonymous mutations were detected, whereas in the metastatic L/N, 44 (58.7%) of 75 were discovered. A total 24 (11.3%) out of 213 non-synonymous mutations were developed in the context of APOBEC signature. Of those, 21 (87.5%) was detected in the primary tumors and 4 (16.7%) was detected in the metastatic L/N. When the mutation profiles between primary tumor and metastatic L/N were compared, 13 (31.7%) of 41 cases showed discrepant mutation profile. There were no statistically significant differences in disease free survival and overall survival between groups showing identical mutation profiles and those with discrepancy between primary and metastatic L/N. Conclusions: Genetic heterogeneity between the primary and L/N metastatic lesions is not infrequent finding to consider when interpreting genomic data based on the result of one site inspection. A large prospective study may be needed to evaluate the impact of genetic heterogeneity on the clinical outcomes of NSCLC patients.en_US
dc.description.sponsorshipThis study was supported by a NSCR grant (HI10C2020) awarded to YS Chang.en_US
dc.language.isoenen_US
dc.publisherBIOMED CENTRAL LTDen_US
dc.subjectGenetic heterogeneityen_US
dc.subjectMutationen_US
dc.subjectNext generation sequencingen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectLung adenocarcinomaen_US
dc.titleGenetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinomaen_US
dc.typeArticleen_US
dc.relation.volume16-
dc.identifier.doi10.1186/s12885-016-2049-z-
dc.relation.page1-9-
dc.relation.journalBMC CANCER-
dc.contributor.googleauthorKim, Eun Young-
dc.contributor.googleauthorCho, Eun Na-
dc.contributor.googleauthorPark, Heae Surng-
dc.contributor.googleauthorKim, Arum-
dc.contributor.googleauthorHong, Ji Young-
dc.contributor.googleauthorLim, Seri-
dc.contributor.googleauthorYoun, Jong Pil-
dc.contributor.googleauthorHwang, Seung Yong-
dc.contributor.googleauthorChang, Yoon Soo-
dc.relation.code2016009247-
dc.sector.campusS-
dc.sector.daehakGRADUATE SCHOOL[S]-
dc.sector.departmentDEPARTMENT OF BIONANOTECHNOLOGY-
dc.identifier.pidsyhwang-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE